Carbacyclins, process for the preparation thereof, and use thereof as
medicinal agents
    1.
    发明授权
    Carbacyclins, process for the preparation thereof, and use thereof as medicinal agents 失效
    卡巴菌素,其制备方法及其作为药剂的用途

    公开(公告)号:US5124343A

    公开(公告)日:1992-06-23

    申请号:US141233

    申请日:1988-01-06

    摘要: The invention relates to carbacyclins of general Formula I ##STR1## wherein R.sub.1 is the residue CH.sub.2 OH or ##STR2## with R.sub.2 meaning a hydrogen atom, an alkyl, cycloalkyl, aryl residue, a ##STR3## or heterocyclic residue, or R.sub.1 is the residue ##STR4## with R.sub.3 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms or the residue R.sub.2, orR.sub.1 is the residue ##STR5## wherein m is the number 1 or 2, X is an oxygen atom or a CH.sub.2 -group,A is a trans--CH.dbd.CH- or --.tbd.C--group,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,n is the number 1, 2, or 3,D is a straight-chain alkylene group of 1-5 carbon atoms,E is a --C.tbd.C---bond or a --CR.sub.6 =CR.sub.7 --group wherein R.sub.6 and R.sub.7 are different from each other and mean a hydrogen atom or an alkyl group of 1-5 carbon atoms or a hydrogen atom or a halogen atom, preferably chlorine,R.sub.4 is an alkyl, cycloalkyl, or optionally substituted arly group, or a heterocyclic group,R.sub.5 is a free or functionally modified hydroxy group, andif R.sub.2 means a hydrogen atom, the salts thereof with physiologically compatible bases;to processes for the preparation thereof, and to the use thereof as blood-pressure-lowering agents.

    摘要翻译: 本发明涉及通式I的碳霉素,其中R 1是残基CH 2 OH或R 2,其中R 2表示氢原子,烷基,环烷基,芳基,芳基或杂环残基,或者R 1是 残基其中R3表示分别为1-10个碳原子的烷酰基或烷磺酰基残基或残基R2,或R1为残基,其中m为数1或2,X为氧原子或CH2- 基团,A是反式-CH = CH-或 - 3BOND C-基团,W是游离或官能改性的羟基亚甲基基团,其中OH-基团可以是α或β位置,n是数1,2 或3,D是1-5个碳原子的直链亚烷基,E是-C3OND C键或-CR6 = CR7-基团,其中R6和R7彼此不同,意指氢 原子或1-5个碳原子的烷基或氢原子或卤素原子,优选氯,R4是烷基,环烷基或任选取代的芳基或杂环基团 p,R5是游离或功能改性的羟基,如果R 2表示氢原子,则其与生理上相容的碱的盐; 其制备方法及其作为降血压剂的用途。

    Azaprostacyclins, their preparation and pharmaceutical use
    3.
    发明授权
    Azaprostacyclins, their preparation and pharmaceutical use 失效
    阿沙普罗环素,其制备和药物用途

    公开(公告)号:US4567195A

    公开(公告)日:1986-01-28

    申请号:US591719

    申请日:1984-03-21

    摘要: Azaprostacyclins of Formula I ##STR1## wherein R.sub.1 is hydrogen, alkyl, cycloalkyl, aryl, a heterocyclic residue, or a phenacyl residue optionally substituted on the phenyl ring by bromine, phenyl, alkoxy, or dialkoxy,W is a free or functionally modified carbonyl group or a ##STR2## wherein R.sub.8 is hydrogen or alkyl of 1-5 carbon atoms and R.sub.9 is hydrogen or a readily cleavable ether or acyl residue and wherein the OR.sub.9 -group can be in the .alpha.- or .beta.-position,R.sub.2 is a free or functionally modified hydroxy group,R.sub.3 and R.sub.4 each independently is hydrogen, alkyl of 1-5 carbon atoms, or fluorine,D is alkylene of 1-2 carbon atoms which can be substituted by alkyl groups of 1-5 carbon atoms,R.sub.5 is hydrogen or alkyl of 1-2 carbon atoms or, when D is alkylene of 1 or 2 carbon atoms, R.sub.5, together with R.sub.6, represents a bond,R.sub.6 and R.sub.7 each independently is hydrogen or alkyl of 1-2 carbon atoms, whereinR.sub.6 (R.sub.7) is halogen when R.sub.7 (R.sub.6), respectively, is alkyl of 1-2 carbon atoms orR.sub.5 and R.sub.7 each independently is hydrogen or alkyl of 1-2 carbon atoms whenD and R.sub.6 together form a carbocyclic ring closed via (CH.sub.2).sub.1-3 with D as --CH

    摘要翻译: 式I的阿沙普罗环素其中R 1是氢,烷基,环烷基,芳基,杂环残基或任选在苯环上被溴,苯基,烷氧基或二烷氧基取代的苯甲酰甲基残基,W是游离或 官能改性的羰基或其中R8是氢或1-5个碳原子的烷基,R9是氢或易裂解的醚或酰基残基,其中OR9-基团可以是α-或β-位, R2是游离的或官能改性的羟基,R 3和R 4各自独立地是氢,1-5个碳原子的烷基或氟,D是可以被1-5个碳原子的烷基取代的1-2个碳原子的亚烷基 原子,R5是氢或1-2个碳原子的烷基,或当D是1或2个碳原子的亚烷基时,R5与R6一起代表键,R6和R7各自独立地是氢或1-2碳的烷基 原子,其中当R 7(R 6)分别为1-2个碳原子的烷基或R 5和R 7 eac时,R 6(R 7)为卤素 h独立地为氢或1-2个碳原子的烷基,当D和R6一起形成通过(CH 2)1-3封闭的碳环,其中D为-CH 3且R 6为-CH 2 - ,当R 1为氢时, 其与碱的生理上相容的盐具有有价值的药理学性质,例如降血压和支气管扩张活性。

    Prostaglandin-I.sub.2 derivatives
    4.
    发明授权
    Prostaglandin-I.sub.2 derivatives 失效
    前列腺素I2衍生物

    公开(公告)号:US4191694A

    公开(公告)日:1980-03-04

    申请号:US928126

    申请日:1978-07-26

    摘要: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ;R.sub.2 is hydrogen, C.sub.1-10 alkyl, C.sub.4-10 cycloalkyl, C.sub.6-10 aryl, or a 5 or 6 membered heterocyclic ring having 1-3 hetero atoms selected from O, N and S;R.sub.3 is the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms;W is (a) an OH-substituted methylene group, (b) a ##STR2## wherein the OH-groups in (a) or (b) can be in the .alpha.- or .beta.-position, or (c) such a group wherein the H atom of the OH group is replaced by the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms or by a conventional etherifying OH-blocking group;R.sub.4 is OH or hydroxy whose H atom is replaced as defined for W; andR.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 each independently is hydrogen or alkyl of 1-5 carbon atoms; or R.sub.9 and R.sub.10 together represent a direct bond; and, when R.sub.11 is alkyl, R.sub.10 can also be chlorine;and, for a derivative wherein R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases,have improved prostaglandin activity.

    摘要翻译: 其中R1为OR2或NHR3的式(Ⅰ)所示的前驱体衍生物; R2是氢,C1-10烷基,C4-10环烷基,C6-10芳基或具有1-3个选自O,N和S的杂原子的5或6元杂环; R3是1-15个碳原子的烃羧酸或磺酸的残基; W是(a)OH-取代的亚甲基,(b)其中(a)或(b)中的OH基可以是α或β-位,或(c)这样的基团 其中OH基团的H原子被1-15个碳原子的烃羧酸或磺酸的残基或通过常规的醚化OH-封闭基团取代; R4是OH或羟基,其H原子被替换为W定义; R 5,R 6,R 7,R 8,R 9,R 10和R 11各自独立地为氢或1-5个碳原子的烷基; 或R 9和R 10一起代表直接键; 当R 11为烷基时,R 10也可为氯; 并且对于其中R 2是氢的衍生物,其与生理上相容的碱的盐具有改善的前列腺素活性。

    9-fluoroprostaglandin derivatives, their preparation and use as
medicinal agents
    7.
    发明授权
    9-fluoroprostaglandin derivatives, their preparation and use as medicinal agents 失效
    9-氟前列腺素衍生物,其制备和用作药物

    公开(公告)号:US4789685A

    公开(公告)日:1988-12-06

    申请号:US4733

    申请日:1987-01-20

    摘要: 9-fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, the physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    摘要翻译: 其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基的式I的α-氟仿烷基衍生物。 或R1是残基,其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-,B是-CH2-CH2-,反式-CH = CH-或-C3BOND C,W是游离的或官能改性的羟基亚甲基,其中OH基可以是α或β位,D和E共同是直接键,或D是1-10的直链或支链亚烷基或亚链烯基 可以任选被氟原子取代的碳原子,E是氧或硫,直接键,-C 3 D或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或烷基 R4是游离的或官能改性的羟基,R5是氢,任意取代的脂族基团,例如烷基或卤代取代的烷基,环烷基,任选被取代的芳基或杂环基,当R2是H时,生理上相容的盐 具有有价值的药理学性质,例如作为骨质疏松症或流产者。

    9-Bromoprostaglandins, their preparation, and their use as medicaments
    8.
    发明授权
    9-Bromoprostaglandins, their preparation, and their use as medicaments 失效
    9-溴前列​​腺素,其制剂及其用作药物

    公开(公告)号:US4487953A

    公开(公告)日:1984-12-11

    申请号:US446888

    申请日:1982-12-06

    摘要: Compounds of Formula (I) ##STR1## wherein the 9-bromine atom can be in the .alpha.- or .beta.-position,R.sub.1 is CH.sub.2 OH or C(O)OR.sub.2, wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is C(O)NHR.sub.3 wherein R.sub.3 is an acid residue or R.sub.2 ; andA is --CH.sub.2 --CH.sub.2 -- or cis --CH.dbd.CH--;B is --CH.sub.2 --CH.sub.2 --, trans --CH.dbd.CH--, or --C.tbd.C--;W is a free or functionally modified hydroxymethylene group or a free or functionally modified ##STR2## wherein the OH-group can be in the .alpha.- or .beta.-position; D and E together are a direct bond; orD is straight-chain, branched, or cyclic alkylene of 1-10 carbon atoms, optionally substituted by fluorine atoms; andE is oxygen, sulfur, a direct bond --C.tbd.C--, or --CR.sub.6 .dbd.CR.sub.7 --, wherein R.sub.6 and R.sub.7 are different from each other and each is hydrogen, chlorine, or C.sub.1 -C.sub.4 -alkyl;R.sub.4 is a free or functionally modified hydroxy group;R.sub.5 is hydrogen, alkyl, halo-substituted alkyl, cycloalkyl, optionally substituted aryl, or a heterocyclic group; and, when R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases,are pharmacologically active compounds, e.g., as abortifacients.

    摘要翻译: 式(I)化合物其中9-溴原子可以是α或β-位,R1是CH2OH或C(O)OR2,其中R2是氢,烷基,环烷基,芳基, 或杂环残基; 或R 1为C(O)NHR 3,其中R 3为酸残基或R 2; 并且A是-CH 2 -CH 2 - 或顺式-CH = CH-; B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3位C; W是游离或官能改性的羟基亚甲基或游离或官能改性的“IMAGE”,其中OH基可以是α-或β-位; D和E一起是直接的债券; 或D是1-10个碳原子的直链,支链或环状亚烷基,任选被氟原子取代; 并且E是氧,硫,直接键-C 3或C 6或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或C 1 -C 4 - 烷基; R4是游离的或官能改性的羟基; R5是氢,烷基,卤素取代的烷基,环烷基,任选取代的芳基或杂环基; 并且当R 2为氢时,其与生理上相容的碱的盐是药理活性化合物,例如作为流产者。

    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as
medicinal agents
    9.
    发明授权
    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as medicinal agents 失效
    DELTA 8,9-前列腺素衍生物,其制备和用作药物

    公开(公告)号:US4560786A

    公开(公告)日:1985-12-24

    申请号:US391734

    申请日:1982-06-24

    摘要: .DELTA..sup.8,9 -Prostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 ; A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH;B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--W is a free or functionally modified hydroxymethylene group or free or functionally modified ##STR4## wherein the OH--group can be in the .alpha.-- or .beta.-- position; D and E jointly are a direct bond orD is straight chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen, sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 --, wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine or alkyl;R.sub.4 is free or functionally modified hydroxy andR.sub.5 is an optionally substituted aliphatic group, cycloalkyl, optionally substituted aryl, or a heterocyclic group, and when R.sub.2 is hydrogen, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g. luteolytic and abortifacient activities.

    摘要翻译: DELTA 8,9-式I的前驱体衍生物其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基; 或R 1为,其中R 3为酸残基或R 2; A是-CH 2 -CH 2 - 或顺式-CH = CH; B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3BOND C-W是游离或官能改性的羟基亚甲基或游离或官能改性的“IMAGE”,其中OH-基团可以是α或β - 位置 D和E共同是直接键合,或D是可以任选被氟原子取代的1-10个碳原子的直链或支链亚烷基或亚烯基,并且E是氧,硫,直接键,-C 3 D或 -CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自为氢,氯或烷基; R4是游离的或官能改性的羟基,R 5是任选取代的脂族基,环烷基,任选取代的芳基或杂环基,当R 2是氢时,其与碱的生理上相容的盐具有有价值的药理学性质。 luteolytic和流产活动。

    9-Fluoroprostaglandin derivatives, and use as medicinal agents
    10.
    发明授权
    9-Fluoroprostaglandin derivatives, and use as medicinal agents 失效
    9-氟前列腺素衍生物,用作药物

    公开(公告)号:US4454339A

    公开(公告)日:1984-06-12

    申请号:US395448

    申请日:1982-07-06

    摘要: 9-Fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.-position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    摘要翻译: 其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基的式I的1-氟代衍生物(Ⅰ) 或R1是残基,其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-,B是-CH2-CH2-,反式-CH = CH-或-C3BOND C,W是游离的或官能改性的羟基亚甲基,其中OH基可以是α-或β-位,D和E共同是直接键,或D是1-10的直链或支链亚烷基或亚烯基 可以任选被氟原子取代的碳原子,E是氧或硫,直接键,-C 3 D或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或烷基 R4是游离的或官能改性的羟基,R5是氢,任意取代的脂族基团,例如烷基或卤代取代的烷基,环烷基,任选取代的芳基或杂环基,当R 2是H时,其生理上相容的盐 具有碱性,具有有价值的药理学性质,例如作为纤溶素或流产。